FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044657223> ?p ?o ?g. }

• W3044657223 endingPage "523" @default.
• W3044657223 startingPage "517" @default.
• W3044657223 abstract "Background Clofazimine has been regarded as a promising agent for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD). However, its overall effectiveness in vitro and in the clinic remains unknown. Research Question What is the minimal inhibitory concentration (MIC) of clofazimine in clinical isolates and the association between MICs and treatment outcome? Study Design and Methods MICs for clofazimine were measured in clinical isolates from NTM-PD patients who participated in a prospective study at Seoul National University Hospital. The MIC was determined by using the broth microdilution concentration method. Correlation between MIC and conversion to negative of sputum culture with clofazimine was determined. Results Of a total 189 isolates, 133 strains were Mycobacterium avium complex (MAC) and 40 strains were M abscessus. Although the clofazimine MICs for MAC ranged from 0.031 mg/L to 8 mg/L, the values obtained for M abscessus ranged from 0.031 mg/L to 16 mg/L. Of 20 patients who were treated with a regimen including clofazimine, eight achieved negative conversion of sputum culture. All patients with isolates exhibiting clofazimine MIC values ≤ 0.25 mg/L achieved culture conversion. The likelihood of culture conversion in patients with MIC value ≤ 0.25 mg/L was much higher than that of patients with MIC value > 0.5 mg/L (OR, 39.3; P = .021). Interpretation The MICs of clofazimine varied widely in clinical isolates from patients with NTM-PD. Negative conversion of sputum culture with clofazimine use was associated with a lower MIC value. Clofazimine use could be considered in patients with NTM-PD when the MIC value is ≤ 0.25 mg/L. Trial REGISTRY ClinicalTrials.gov; No.: NCT01616745; URL: www.clinicaltrials.gov. Clofazimine has been regarded as a promising agent for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD). However, its overall effectiveness in vitro and in the clinic remains unknown. What is the minimal inhibitory concentration (MIC) of clofazimine in clinical isolates and the association between MICs and treatment outcome? MICs for clofazimine were measured in clinical isolates from NTM-PD patients who participated in a prospective study at Seoul National University Hospital. The MIC was determined by using the broth microdilution concentration method. Correlation between MIC and conversion to negative of sputum culture with clofazimine was determined. Of a total 189 isolates, 133 strains were Mycobacterium avium complex (MAC) and 40 strains were M abscessus. Although the clofazimine MICs for MAC ranged from 0.031 mg/L to 8 mg/L, the values obtained for M abscessus ranged from 0.031 mg/L to 16 mg/L. Of 20 patients who were treated with a regimen including clofazimine, eight achieved negative conversion of sputum culture. All patients with isolates exhibiting clofazimine MIC values ≤ 0.25 mg/L achieved culture conversion. The likelihood of culture conversion in patients with MIC value ≤ 0.25 mg/L was much higher than that of patients with MIC value > 0.5 mg/L (OR, 39.3; P = .021). The MICs of clofazimine varied widely in clinical isolates from patients with NTM-PD. Negative conversion of sputum culture with clofazimine use was associated with a lower MIC value. Clofazimine use could be considered in patients with NTM-PD when the MIC value is ≤ 0.25 mg/L. ClinicalTrials.gov; No.: NCT01616745; URL: www.clinicaltrials.gov. ResponseCHESTVol. 160Issue 1PreviewWe appreciate the comments from Drs Aksamit and Marras on our article, which reported the correlation between the minimal inhibitory concentration (MIC) of clofazimine and its clinical impact among patients with Mycobacterium avium complex and M abscessus pulmonary disease.1 The authors raised several crucial issues. Full-Text PDF Clofazimine Drug Susceptibility Testing for Nontuberculous Mycobacteria: A Call to ArmsCHESTVol. 160Issue 1PreviewWe read with interest the study in CHEST (February 2021) by Kwak et al1 regarding the association between clofazimine minimal inhibitory concentration (MIC) and treatment outcomes for Mycobacterium avium complex (MAC) and M abscessus. Full-Text PDF" @default.
• W3044657223 created "2020-07-29" @default.
• W3044657223 creator A5000808086 @default.
• W3044657223 creator A5055855310 @default.
• W3044657223 creator A5062742934 @default.
• W3044657223 creator A5067411233 @default.
• W3044657223 creator A5070963664 @default.
• W3044657223 creator A5082180408 @default.
• W3044657223 date "2021-02-01" @default.
• W3044657223 modified "2023-10-12" @default.
• W3044657223 title "Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome" @default.
• W3044657223 cites W1988165232 @default.
• W3044657223 cites W1993911058 @default.
• W3044657223 cites W2013416277 @default.
• W3044657223 cites W2037976634 @default.
• W3044657223 cites W2114152855 @default.
• W3044657223 cites W2114658413 @default.
• W3044657223 cites W2118403978 @default.
• W3044657223 cites W2134490477 @default.
• W3044657223 cites W2141175182 @default.
• W3044657223 cites W2142447693 @default.
• W3044657223 cites W2159254579 @default.
• W3044657223 cites W2339059423 @default.
• W3044657223 cites W2534216031 @default.
• W3044657223 cites W2552440548 @default.
• W3044657223 cites W2600283684 @default.
• W3044657223 cites W2610803530 @default.
• W3044657223 cites W2621225386 @default.
• W3044657223 cites W2726707852 @default.
• W3044657223 cites W2738646765 @default.
• W3044657223 cites W2766733233 @default.
• W3044657223 cites W2793567629 @default.
• W3044657223 cites W2800588315 @default.
• W3044657223 cites W2802476832 @default.
• W3044657223 cites W2884838954 @default.
• W3044657223 cites W2911323192 @default.
• W3044657223 cites W2921372111 @default.
• W3044657223 cites W2922557056 @default.
• W3044657223 cites W2995199373 @default.
• W3044657223 doi "https://doi.org/10.1016/j.chest.2020.07.040" @default.
• W3044657223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32712225" @default.
• W3044657223 hasPublicationYear "2021" @default.
• W3044657223 type Work @default.
• W3044657223 sameAs 3044657223 @default.
• W3044657223 citedByCount "21" @default.
• W3044657223 countsByYear W30446572232020 @default.
• W3044657223 countsByYear W30446572232021 @default.
• W3044657223 countsByYear W30446572232022 @default.
• W3044657223 countsByYear W30446572232023 @default.
• W3044657223 crossrefType "journal-article" @default.
• W3044657223 hasAuthorship W3044657223A5000808086 @default.
• W3044657223 hasAuthorship W3044657223A5055855310 @default.
• W3044657223 hasAuthorship W3044657223A5062742934 @default.
• W3044657223 hasAuthorship W3044657223A5067411233 @default.
• W3044657223 hasAuthorship W3044657223A5070963664 @default.
• W3044657223 hasAuthorship W3044657223A5082180408 @default.
• W3044657223 hasConcept C126322002 @default.
• W3044657223 hasConcept C142724271 @default.
• W3044657223 hasConcept C176947019 @default.
• W3044657223 hasConcept C203014093 @default.
• W3044657223 hasConcept C2776111603 @default.
• W3044657223 hasConcept C2776297342 @default.
• W3044657223 hasConcept C2776301714 @default.
• W3044657223 hasConcept C2777768864 @default.
• W3044657223 hasConcept C2777931070 @default.
• W3044657223 hasConcept C2778679867 @default.
• W3044657223 hasConcept C2779912665 @default.
• W3044657223 hasConcept C2780374374 @default.
• W3044657223 hasConcept C2780695269 @default.
• W3044657223 hasConcept C2781069245 @default.
• W3044657223 hasConcept C2781413609 @default.
• W3044657223 hasConcept C3019249092 @default.
• W3044657223 hasConcept C501593827 @default.
• W3044657223 hasConcept C71924100 @default.
• W3044657223 hasConcept C81396022 @default.
• W3044657223 hasConcept C86803240 @default.
• W3044657223 hasConcept C89423630 @default.
• W3044657223 hasConceptScore W3044657223C126322002 @default.
• W3044657223 hasConceptScore W3044657223C142724271 @default.
• W3044657223 hasConceptScore W3044657223C176947019 @default.
• W3044657223 hasConceptScore W3044657223C203014093 @default.
• W3044657223 hasConceptScore W3044657223C2776111603 @default.
• W3044657223 hasConceptScore W3044657223C2776297342 @default.
• W3044657223 hasConceptScore W3044657223C2776301714 @default.
• W3044657223 hasConceptScore W3044657223C2777768864 @default.
• W3044657223 hasConceptScore W3044657223C2777931070 @default.
• W3044657223 hasConceptScore W3044657223C2778679867 @default.
• W3044657223 hasConceptScore W3044657223C2779912665 @default.
• W3044657223 hasConceptScore W3044657223C2780374374 @default.
• W3044657223 hasConceptScore W3044657223C2780695269 @default.
• W3044657223 hasConceptScore W3044657223C2781069245 @default.
• W3044657223 hasConceptScore W3044657223C2781413609 @default.
• W3044657223 hasConceptScore W3044657223C3019249092 @default.
• W3044657223 hasConceptScore W3044657223C501593827 @default.
• W3044657223 hasConceptScore W3044657223C71924100 @default.
• W3044657223 hasConceptScore W3044657223C81396022 @default.
• W3044657223 hasConceptScore W3044657223C86803240 @default.
• W3044657223 hasConceptScore W3044657223C89423630 @default.

• next